Immunotherapy at Any Line of Treatment Improves Survival in Patients With Advanced Metastatic Non‐small Cell Lung Cancer (NSCLC) Compared With Chemotherapy (Quijote‐CLICaP)
Thoracic Cancer - Australia
doi 10.1111/1759-7714.13272
Full Text
Open PDFAbstract
Available in full text
Date
December 12, 2019
Authors
Publisher
Wiley